Class 'A' Ordinary Shares

Trinity Biotech plc

IDA Business Park, County Wicklow, L2, A98 H5C8

Item 2(a) of the Original Schedule 13D is hereby amended and restated in full as follows: This Amendment No. 7 is being filed jointly by DAYLI Holdings, DAYLI Fountainhead and DAYLI Partners. DAYLI Fountainhead owns all of the equity interests in DAYLI Holdings and DAYLI Partners is the general partner of DAYLI Fountainhead. Certain information regarding each director and executive officer of the DAYLI Filers is set forth on Annex C filed herewith.

Item 2(b) of the Original Schedule 13D is hereby amended and restated in full as follows: The address of each of the DAYLI Filers is 15F, 201, Teheran-ro, Gangnam-gu, Seoul, Republic of Korea.

Item 2(c) of the Original Schedule 13D is hereby amended and restated in full as follows: The principal business of DAYLI Partners is to acquire, hold and dispose of interests in various companies for investment purposes and to take all actions incident thereto. The principal business of each of DAYLI Holdings and DAYLI Fountainhead is to acquire, hold and dispose of interests in MiCo IVD for investment purposes.

Item 2(e) of the Original Schedule 13D is hereby amended and restated in full as follows: During the last five years, neither the DAYLI Filers, nor any person identified in Item 2(a), has been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

Item 2(f) of the Original Schedule 13D is hereby amended and restated in full as follows: Each of the DAYLI Filers was formed in South Korea.

Item 5(a) of the Original Schedule 13D is hereby amended and restated in full as follows: The information set forth under the final paragraph of Item 4 and the cover page of this Amendment No. 7 is incorporated herein by reference into this Item 5. Following the completion of the 2025 MiCo IVD Purchase by AI n M, the DAYLI Filers are no longer deemed to beneficially own any Ordinary Shares.

Item 5(b) of the Original Schedule 13D is hereby amended and restated in full as follows: The information set forth under the final paragraph of Item 4 and the cover page of this Amendment No. 7 is incorporated herein by reference into this Item 5. Following the completion of the 2025 MiCo IVD Purchase by AI n M, the DAYLI Filers are no longer deemed to beneficially own any Ordinary Shares.

Item 5(c) of the Original Schedule 13D is hereby amended and restated in full as follows: Except as set forth in the Original Schedule 13D and this Amendment No. 7, neither the DAYLI Filers nor, to the best knowledge of the DAYLI Filers, any other person named in Item 2, has engaged in any transaction in Ordinary Shares during the past 60 days.

Item 5(d) of the Original Schedule 13D is hereby amended and restated in full as follows: Not Applicable.

Item 5(e) of the Original Schedule 13D is hereby amended and restated in full as follows: The 2025 MiCo IVD Purchase by AI n M was executed and closed on December 2, 2025, following which time the DAYLI Filers ceased to beneficially own more than five percent of the Ordinary Shares of the Issuer.